



National Cancer Research Institute (NCRI)

Clinical and Translational Radiotherapy Research Working Group (CTRad)

Remit of CTRad

CTRad is an NCRI initiative setup in 2009 to focus on clinical and translational issues relating to radiotherapy and radiobiology, as well as developing a portfolio of practice-changing trials. CTRad has also been tasked with actively promoting translation of new discoveries into practice.

CTRad's mission statement

To maximise quantity and quality of life for patients receiving radiotherapy by optimising tumour control and minimising toxicity. Click <u>here</u> to see CTRad's strategic vision 2018-2021.

Specific Workstream Member and CTRad Member Role Profiles

CTRad Workstream Members ('Workstream Members')

Composition and membership

Each Workstream comprises 8-12 Members, up to a maximum of 40 across all four Workstreams. Membership of the Workstreams will be multidisciplinary, ensuring that all relevant scientific/medical disciplines are able to contribute.

Appointment to a Workstream is for a three year period in the first instance, with the option to apply for a further three year extension. CTRad Workstream Membership is voluntary and will not be remunerated. Active engagement with the Workstream and meaningful contributions to its activities are crucial and will be reviewed on an annual basis.

Workstream Members will be selected through a competitive application process.

Duties and responsibilities of Workstream Members

Workstream Members will be expected to engage enthusiastically and productively with Workstream activities and working groups, to attend Workstream and CTRad's Proposals Guidance Meetings,¹ and to contribute to the maintenance and further development of CTRad's remit by:

¹ As a guide, Workstream face-to-face and teleconference meetings include but are not restricted to:

[•] Workstream teleconference meetings: 1 – 1.5 hours, once every four to six months, up to three times a year

[•] Workstream face-to-face meetings: half-day, up to twice a year

[•] Proposals guidance face-to-face meetings: half-day, up to twice a year

[•] Participation at other meetings for individual projects, as agreed with the Executive Group.

- Ensuring expectations of CTRad's Executive Group are understood, including seeking clarification where further direction is necessary and taking on defined tasks within their appointed Workstream e.g. mentoring consumers and trainees, chairing workpackages
- Actively engaging with proposals under development within CTRad's portfolio; e.g. mentoring new investigators, offering information and advice to collaborators, presenting findings as appropriate
- Generating ideas for new radiotherapy trials (ideally as Chief Investigator or co-Investigator)
- Contributing to the development of high quality applications to funding bodies through the review and refinement of trial concepts and proposals submitted to CTRad
- Contributing to consultation exercises (e.g. NICE) undertaken by CTRad as requested
- Contributing to CTRad's reports to its funders and to relevant peer-review of the portfolio
- Adhering to NCRI branding guidelines when communicating on behalf of CTRad or in capacity as a Workstream Member
- Providing expert advice to CTRad's Executive Group, NCRI funders and the wider cancer community as required.

Workstream Members are also required to abide by the <u>NCRI expenses policy</u> when claiming travel costs relating to meeting attendance.

Qualities required in Workstream Members

Workstream Members should have a track record of participation in radiotherapy research and be able to contribute actively to the work of their appointed Workstream, by demonstrating the following:

- Experience of collaborative clinical trials activity in a leadership capacity
- Evidence of publications and/or presentations nationally/internationally
- Enthusiasm and commitment to developing inclusive, UK-wide approaches to radiotherapy and associated radiobiology research
- There will be a focus on including less experienced members who show potential to become leaders in the field in the future, while continuing to include some highly experienced researchers with strong track records.

CTRad General Members ('CTRad Members')

Composition and membership

CTRad general membership will be open to all individuals working within or connected with the UK radiotherapy community. CTRad general membership is voluntary and will not be remunerated. CTRad general membership will be renewable every three years.

Benefits of CTRad Membership

CTRad Members will have access to information, proposals guidance meetings and CTRad workshops and will be offered opportunities to participate in specific activities, including focused, project-driven working groups pertaining to their field(s) of expertise. Project specific working groups are a key component of CTRad's activity and are expected to increase in number and scope over the next three years. The working groups will provide opportunities for CTRad Members to play active and recognised roles within the organisation, and to contribute to the delivery of CTRad's objectives.

Qualities required in CTRad Members


CTRad Members should have enthusiasm and commitment to developing inclusive, UK-wide approaches to radiotherapy and associated radiobiology research.

Code of conduct

The NCRI's purpose is to improve health and quality of life by accelerating progress in cancer-related research, through collaboration. To help us achieve this, CTRad Workstream and general members are asked to:

- Abide by the values highlighted in the NCRI strategy, by being <u>collaborative</u>, <u>dynamic</u> and <u>determined</u>, and acting with <u>integrity</u>, <u>professionalism</u> and <u>intelligence</u>
- Always act in the best interests of the charity and support NCRI's 4 key strategic aims, to:
 - Ensure a coordinated portfolio of research related to cancer
 - Seize opportunities and address challenges in research relevant to cancer
 - Continuously improve the quality and relevance of research related to cancer
 - Accelerate the translation of cancer-related research into practice.

Leadership and membership structure of CTRad from April 2018



Last updated 21 December 2017